natgillin/translations-raw huggingface dataset:
In TRITON-TIMI 38 and 3 of the cohort studies (n= 3,516; Collet, Sibbing, Giusti), patients with an impaired metaboliser status (intermediate and poor combined) had a higher rate of cardiovascular events (death, myocardial infarction, and stroke) or stent thrombosis compared to extensive metabolisers.
V TRITON-TIMI 38 in 3 kohortnih študijah (n = 3.516; Collet, Sibbing, Giusti) so imeli bolniki s statusom nezadostnega presnavljalca (srednji in slabi metabolizatorji skupaj) večji delež kardiovaskularnih dogodkov (smrt, miokardni infarkt, možganska kap) ali tromboze na opornici kot močni metabolizatorji.
If you become pregnant while taking Clopidogrel BMS, consult your doctor immediately as it is recommended not to take clopidogrel while you are pregnant.
Če med zdravljenjem z zdravilom Clopidogrel BMS zanosite, se takoj posvetujte s svojim zdravnikom, saj jemanje klopidogrela med nosečnostjo ni priporočljivo.
If you forget to take Clopidogrel BMS:
Če ste pozabili vzeti zdravilo Clopidogrel BMS:
In CURE, the major bleeding event rate for clopidogrel+ASA was dose-dependent on ASA (<100mg: 2.6%; 100-200mg: 3.5%; >200mg: 4.9%) as was the major bleeding event rate for placebo+ASA (<100mg: 2.0%; 100-200mg: 2.3%; >200mg: 4.0%).
V CURE je bil delež dogodkov z velikimi krvavitvami za klopidogrel in ASA odvisen od odmerka ASA (< 100 mg: 2,6 %; 100-200 mg: 3,5 %; > 200 mg: 4,9 %), kakor tudi delež velikih krvavitev za placebo in ASA (< 100 mg: 2,0 %; 100-200 mg: 2,3 %; > 200 mg: 4,0 %).
Excipients: each tablet contains 12 mg lactose and 13.2 mg hydrogenated castor oil.
Pomožne snovi: ena tableta vsebuje 12 mg laktoze in 13,2 mg hidrogeniranega ricinusovega olja.
Newcastle Upon Tyne, Tyne & Wear NE3 3TT - UK, United Kingdom and/or
Newcastle Upon Tyne, Tyne& Wear NE3 3TT - UK, Velika Britanija Sanofi Winthrop Industrie
Drugs that inhibit CYP2C19 include omeprazole and esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine, ciprofloxacin, cimetidine, carbamazepine,
Med zdravili, ki zavirajo CYP2C19, so omeprazol in esomeprazol, fluvoksamin, fluoksetin, moklobemid, vorikonazol, flukonazol, tiklopidin, ciprofloksacin, cimetidin, karbamazepin,
In addition, clinical tolerance was good in
Dodatno je bilo klinično
Poor metabolism: CYP2C19*2/*2, *2/*3 or *3/*3
Slaba presnova: CYP2C19*2/*2, *2/*3 ali *3/*3 2
Clopidogrel should be given as a single daily dose of 75 mg with or without food.
Klopidogrel se mora dajati kot enkratni dnevni odmerek 75 mg, z ali brez hrane.
The active thiol metabolite which has been isolated in vitro, binds rapidly and irreversibly to platelet receptors, thus inhibiting platelet aggregation.
In vitro izolirani aktivni tiolski presnovek se hitro in ireverzibilno veže na trombocitne receptorje in tako zavre agregacijo
If you take more Clopidogrel BMS than you should: Contact your doctor or the nearest hospital emergency department because of the increased risk of
Če ste vzeli večji odmerek zdravila Clopidogrel BMS, kot bi smeli: Zaradi povečanega tveganja krvavitve se posvetujte s svojim zdravnikom ali oddelkom najbližje
Reduced CYP2C19 metabolism in intermediate and poor metabolisers decreased the Cmax and AUC of the active metabolite by 30-50% following 300- or 600-mg loading doses and 75-mg maintenance doses.
Zmanjšana presnova s CYP2C19 pri srednjih in slabih presnavljalcih je po 300- ali 600-mg polnilnem odmerku in 75-mg vzdrževalnem odmerku zmanjšala Cmax in AUC aktivnega presnovka za 30 do 50 %.
Serious haemorrhage, haemorrhage of operative wound, vasculitis, hypotension Respiratory tract bleeding (haemoptysis, pulmonary haemorrhage), bronchospasm, interstitial pneumonitis
Resne krvavitve, krvavitev operacijske rane, vaskulitis, hipotenzija Krvavitve v dihalih (hemoptiza, pljučna krvavitev), bronhospazem, intersticijski pnevmonitis
Rare side effect (affects 1 to 10 patients in 10,000): Vertigo.
Redki neželeni učinki (pojavijo se pri 1 do 10 od 10.000 bolnikov): Vrtoglavica.
For the 7, 14, 28 and 84 tablets pack sizes, you can check the day on which you last took a tablet of Clopidogrel BMS by referring to the calendar printed on the blister.
Na koledarčku, ki je natisnjen na pretisnem omotu pri pakiranjih po 7, 14, 28 in 84 tablet, lahko preverite, kateri dan ste zadnjič vzeli tableto klopidogrela.
Excipients: each tablet contains 3 mg lactose and 3.3 mg hydrogenated castor oil.
Pomožne snovi: ena tableta vsebuje 3 mg laktoze in 3,3 mg hidrogeniranega ricinusovega olja.
This medicinal product contains hydrogenated castor oil which may cause stomach upset and
Zdravilo vsebuje hidrogenirano ricinusovo olje, ki lahko razdraži želodec in povzroči drisko.
Clopidogrel BMS 75-mg film-coated tablets are round, biconvex, pink, engraved on one side with the number ‘75' and on the other side with the number ‘1171'.
Clopidogrel BMS 75 mg filmsko obložene tablete so okrogle, bikonveksne , rožnate tablete, z vtisnjeno številko “75” na eni strani in številko “1171” na drugi strani.
Very rare side effects (affects less than 1 patient in 10,000): Jaundice; severe abdominal pain with or without back pain; fever, breathing difficulties sometimes associated with cough; generalised allergic reactions; swelling in the mouth; blisters of the skin; skin allergy; inflammation of the mouth
Zelo redki neželeni učinki (pojavijo se pri manj kot 1 od 10.000 bolnikov): zlatenica, huda bolečina v trebuhu z ali brez bolečine v hrbtu, zvišana telesna temperatura, težave pri dihanju, ki so včasih povezane s kašljem, splošne alergijske reakcije, oteklina v ustih, mehurji na koži, kožna alergija, vnetje v ustih (stomatitis), znižanje krvnega tlaka, zmedenost, halucinacije, bolečine v sklepih,
There is no evidence that other drugs that reduce stomach acid such as H2 blockers or antacids interfere with antiplatelet activity of clopidogrel.
Ni dokazov, da druga zdravila za zmanjševanje želodčne kisline, npr. zaviralci H2 ali antacidi, ovirajo antitrombocitno delovanje klopidogrela.
CYP2C19 Phenotype and Genotype Frequency Frequency (%)
Pogostnost fenotipov in genotipov CYP2C19 Pogostnost (%)
Concomitant use of drugs that inhibit CYP2C19 should be discouraged (see section 4.5 for a list of CYP2C19 inhibitors, see also section 5.2).
Sočasno naj ne bi uporabljali zdravil, ki zavirajo CYP2C19 (za seznam zaviralcev CYP2C19 glejte poglavje 4.5; glejte tudi poglavje 5.2).
Extensive metabolism: CYP2C19*1/*1
Obsežna prenova: CYP2C19*1/*1
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Obvestite svojega zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali katerokoli zdravilo,
You should also be given acetylsalicylic acid (a substance present in many medicines used to relieve pain and lower fever as well as to prevent blood clotting) by your doctor.
Zdravnik vam bo moral predpisati tudi acetilsalicilno kislino (učinkovina, ki je prisotna v številnih zdravilih proti bolečinam in za zniževanje zvišane telesne temperature, kakor tudi za
The use of oral anticoagulants (medicines used to reduce blood clotting) with Clopidogrel BMS is not
Uporaba peroralnih antikoagulantov (zdravil, ki se uporabljajo za zmanjševanje strjevanja krvi) z
If you have experienced severe chest pain (unstable angina or heart attack), your doctor may give you 300 mg of Clopidogrel BMS (1 tablet of 300 mg or 4 tablets of 75 mg) once at the start of treatment.
Če ste imeli hudo bolečino v prsih (nestabilna angina pektoris ali srčna kap), vam lahko zdravnik na začetku zdravljenja da enkrat 300 mg zdravila Clopidogrel BMS (eno 300-mg tableto ali štiri 75-mg tablete).
This 300 mg tablet of clopidogrel is intended for use as a loading dose in patients suffering from
300-mg tableta klopidogrela je namenjena kot udarni odmerek pri bolnikih z akutnim
In COMMIT, the overall rate of noncerebral major bleeding or cerebral bleeding was low and similar in both groups (0.6% versus 0.5% in the clopidogrel + ASA and the placebo + ASA groups,
V študiji COMMIT je bil skupni delež večjih necerebralnih krvavitev ali cerebralne krvavitve nizek in podoben v obeh skupinah (0,6 % v skupini s klopidogrelom in ASA ter 0,5 % v skupini s placebom in
Other side effects reported with Clopidogrel BMS are: Common side effects (affects 1 to 10 patients in 100): Diarrhoea, abdominal pain, indigestion or
Drugi neželeni učinki, o katerih so poročali s klopidogrelom so: Pogosti neželeni učinki (pojavijo se pri 1 do 10 od 100 bolnikov): Driska, bolečina v trebuhu, slaba
Then, the usual dose is one 75-mg tablet of Clopidogrel BMS per day to be taken orally with or without food, and at the same time each day.
Nato je običajni odmerek ena 75-mg tableta zdravila Clopidogrel BMS na dan, ki jo lahko vzamete s hrano ali brez nje; odmerek morate jemati vsak dan ob istem času.
Clopidogrel BMS 300-mg film-coated tablets are oblong, pink, engraved on one side with the number ‘300' and on the other side with the number ‘1332'.
Clopidogrel BMS 300 mg filmsko obložene tablete so podolgovate, rožnate, z vtisnjeno številko “300” na eni strani in številko “1332” na drugi strani.
In particular, in a post-hoc analysis in 2,172 patients (17% of the total CURE population) who underwent stent placement (Stent-CURE), the data showed that clopidogrel compared to placebo, demonstrated a significant RRR of 26.2% favouring clopidogrel for the co-primary endpoint (CV death, MI, stroke) and also a significant RRR of 23.9% for the second coprimary endpoint (CV death, MI, stroke or refractory ischaemia).
Zlasti post hoc analiza podatkov 2172 bolnikov (17 % celotne populacije CURE), ki so jim namestili žilno opornico (Stent-CURE), je ob klopidogrelu v primerjavi s placebom pokazala značilno, 26,2 % zmanjšanje RT za sestavljen primarni opazovani dogodek (srčnožilna smrt, miokardni infarkt, možganska kap) in tudi značilno, 23,9 % zmanjšanje RT za drug sestavljen primarni opazovani dogodek (srčno-žilna smrt, miokardni infarkt, možganska kap ali neodzivna ishemija).
You should specifically tell your doctor if you take a non-steroidal anti-inflammatory drug, usually used to treat painful and/or inflammatory conditions of muscle or joints, or if you take heparin or any other medicine used to reduce blood clotting, or if you take a proton pump inhibitor (e.g, omeprazole)
Še posebej pomembno je, da obvestite svojega zdravnika, če jemljete nesteroidna protivnetna zdravila, ki se običajno uporabljajo za lajšanje bolečine in/ali vnetja mišic ali sklepov, ali če jemljete heparin ali katerokoli drugo zdravilo, ki se uporablja za zmanjševanje strjevanja krvi, ali če jemljete kakšen zaviralec protonske črpalke (npr. omeprazol) zaradi težav z želodcem.
Furthermore, the pharmacodynamic activity of clopidogrel was not significantly influenced by the co-administration of phenobarbital, cimetidine or oestrogen.
Poleg tega na farmakodinamično aktivnost klopidogrela ni pomembno vplivala sočasna uporaba fenobarbitala, cimetidina ali estrogena.
If Clopidogrel BMS is supplied in PVC/PVDC/aluminium blisters, store below 30°C.
Zdravilo Clopidogrel BMS, ki je na voljo v PVC/PVDC/alu pretisnih omotih, shranjujte pri temperaturi do 30°C.
- signs of liver problems such as yellowing of the skin and/or the eyes (jaundice), whether or not associated with bleeding which appears under the skin as red pinpoint dots and/or confusion (see section 2 ‘Take special care with Clopidogrel BMS').
To so lahko znaki redkega zmanjšanja števila določenih krvnih celic, - znaki jetrnih težav, kot je porumenelost kože in/ali oči (zlatenica), ki so lahko, ali pa ne, povezani s krvavitvijo, ki se pojavi pod kožo kot drobne rdeče pike, in/ali zmedenostjo (glejte poglavje 2 »Bodite posebno pozorni pri jemanju zdravila Clopidogrel BMS«).
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER/Boxes of 30, 50x1, 90 or 100 tablets
PRETISNI OMOT / Škatle po 30, 50x1, 90 ali 100 tablet
EXPIRY DATE EXP {MM/YYYY}
EXP: {MM/LLLL}
PVC/PVDC/Aluminium blisters or all aluminium blisters in cardboard cartons containing 7, 14, 28, 30, 84, 90 and 100 film-coated tablets.
PVC/PVDC/aluminijasti pretisni omoti ali pretisni omoti iz aluminija, ki vsebujejo 7,14, 28, 30, 84, 90
Clopidogrel BMS belongs to a group of medicines called antiplatelet medicinal products.
Clopidogrel BMS spada v skupino zdravil, ki se imenujejo zaviralci agregacije trombocitov.
While taking Clopidogrel BMS, consult your doctor about the breast-feeding of a baby.
Med jemanjem zdravila Clopidogrel BMS se o dojenju posvetujte z zdravnikom.
In a subgroup analysis by qualifying condition (myocardial infarction, ischaemic stroke, and PAD) the benefit appeared to be strongest (achieving statistical significance at p = 0.003) in patients enrolled due to PAD (especially those who also had a history of myocardial infarction) (RRR = 23.7%; CI: 8.9 to 36.2) and weaker (not significantly different from ASA) in stroke patients (RRR = 7.3%; CI: -5.7 to 18.7 [p=0.258]).
Pri analizi podskupin glede na vključitveni pogoj (miokardni infarkt, ishemična kap in periferna arterijska bolezen/PAD/) je videti najmočnejšo korist (doseganje statistične značilnosti pri p=0,003) pri bolnikih, vključenih zaradi PAD (zlasti pri tistih, ki so doživeli tudi miokardni infarkt) (zmanjšanje RT=23,7 %; IZ: 8,9 do 36,2), in šibkejšo (ni bila pomembno različna od ASA) pri bolnikih s kapjo (zmanjšanje RT=7,3 %; IZ: -5,7 do 18,7 [p=0,258]).
Acute liver failure, hepatitis, abnormal liver function test
Akutna odpoved jeter, hepatitis, nenormalni testi jetrne funkcije podkožja kožne krvavitve (purpura)
Glycoprotein IIb/IIIa inhibitors: clopidogrel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions that receive concomitant glycoprotein IIb/IIIa inhibitors (see section 4.4).
Zaviralci glikoproteina IIb/IIIa: klopidogrel moramo uporabljati previdno pri bolnikih, ki imajo lahko tveganje za povečano krvavitev zaradi poškodbe, kirurškega posega ali drugih patoloških stanj, ko prejemajo sočasno zaviralce glikoproteina IIb/IIIa (glejte poglavje 4.4).
The other ingredients are mannitol (E421), hydrogenated castor oil, microcrystalline cellulose, macrogol 6000 and low-substituted hydroxypropylcellulose in the tablet core, and lactose (milk sugar), hypromellose (E464), triacetin (E1518), red iron oxide (E172), titanium dioxide (E171), and carnauba
Pomožne snovi so: manitol (E421), hidrogenirano ricinusovo olje, mikrokristalna celuloza, makrogol 6000 in delno substituirana hidroksipropilceluloza v jedru tablete in laktoza (mlečni sladkor), hipromeloza (E464), triacetin (E1518), rdeč železov oksid (E172), titanov dioksid (E171) in
The other ingredients are mannitol (E421), hydrogenated castor oil, microcrystalline cellulose, macrogol 6000 and low-substituted hydroxypropylcellulose in the tablet core, and lactose (milk sugar), hypromellose (E464), triacetin (E1518), red iron oxide (E172), titanium dioxide (E171), and carnauba wax in the tablet coating.
Pomožne snovi so: manitol (E421), hidrogenirano ricinusovo olje, mikrokristalna celuloza, makrogol 6000 in delno substituirana hidroksipropilceluloza v jedru tablete in laktoza (mlečni sladkor), hipromeloza (E464), triacetin (E1518), rdeč železov oksid (E172), titanov dioksid (E171) in karnauba vosek v oblogi tablete.
Clopidogrel BMS is supplied in cardboard cartons containing 4x1, 30x1 and 100x1 tablets in all aluminium perforated unit-dose blisters.
Zdravilo Clopidogrel BMS je na voljo v škatlah, ki vsebujejo 4x1, 30x1 in 100x1 tableto v perforiranih pretisnih omotih za enkratni odmerek, ki so v celoti iz aluminija.
Although the evidence of CYP2C19 inhibition varies within the class of Proton Pump Inhibitors, clinical studies suggest an interaction between clopidogrel and possibly all members of this class.
Izsledki o zaviranju CYP2C19 se v skupini zaviralcev protonske črpalke sicer razlikujejo, vendar klinične študije kažejo na medsebojno delovanje med klopidogrelom in morda vsemi pripadniki te skupine.
• If you have a medical condition that is currently causing bleeding such as a stomach ulcer or bleeding within the brain;
BMS; - če imate zdravstveno stanje, ki trenutno povzroča krvavitev, kot je rana na želodcu ali krvavitev v možganih; - če imate hudo jetrno obolenje.
Aluminium perforated unit-dose blisters in cardboard cartons containing 4x1, 30x1 and 100x1 film-coated tablets.
Aluminijski perforirani pretisni omoti za enkratni odmerek v kartonskih škatlah, ki vsebujejo 4 x 1, 30 x 1 in 100 x 1 filmsko obloženo tableto.
- You have a condition of hardening of arteries (also known as atherosclerosis), and - You have previously experienced a heart attack, stroke or have a condition known as peripheral
Clopidogrel BMS vam je predpisan za pomoč pri preprečevanju nastajanja krvnih strdkov in za zmanjšanje tveganja teh hudih dogodkov, ker: - imate stanje otrdelih arterij (znano tudi kot ateroskleroza), in - ste predhodno doživeli srčni napad, kap ali imeli stanje, ki je znano kot periferna arterijska
Clopidogrel BMS also contains hydrogenated castor oil which may cause stomach upset or diarrhoea.
Zdravilo Clopidogrel BMS vsebuje tudi hidrogenirano ricinusovo olje, ki lahko povzroči želodčne
In the intention to treat analysis, 939 events were observed in the clopidogrel group and 1,020 events with ASA (relative risk reduction (RRR) 8.7%, [95% CI: 0.2 to 16.4]; p = 0.045), which corresponds, for every 1,000 patients treated for 2 years, to 10 [CI: 0 to 20] additional patients being prevented from experiencing a new ischaemic event.
Pri analizi vključenih bolnikov (“intention to treat analysis”) so v skupini, ki je prejemala klopidogrel, opazili 939 dogodkov in v skupini, ki je prejemala ASA, 1.020 dogodkov (zmanjšanje relativnega tveganja (RT) 8,7 %, [95 % IZ: 0,2 do 16,4]; p=0,045), kar ustreza preprečevanju pojava novega ishemičnega dogodka na vsakih 1.000 bolnikov, zdravljenih 2 leti, dodatnim 10 [IZ: 0 do 20] bolnikom.
EU/1/08/464/015 - Cartons of 4x1 film-coated tablets in all aluminium perforated unit-dose blisters EU/1/08/464/016 - Cartons of 30x1 film-coated tablets in all aluminium perforated unit-dose blisters EU/1/08/464/017 - Cartons of 100x1 film-coated tablets in all aluminium perforated unit-dose blisters
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/08/464/015 4x1 filmsko obloženih tablet EU/1/08/464/016 30x1 filmsko obloženih tablet EU/1/08/464/017 100x1 filmsko obloženih tablet
What Clopidogrel BMS looks like and contents of the pack
Izgled zdravila Clopidogrel BMS in vsebina pakiranja
SPECIAL STORAGE CONDITIONS Store below 30°C (for PVC/PVDC/aluminium blisters) Or No special storage conditions (for all aluminium blisters)
POSEBNA NAVODILA ZA SHRANJEVANJE Shranjujte pri temperaturi do 30°C (za PVC/PVDC/alu pretisne omote).
If Clopidogrel BMS is supplied in all aluminium blisters, it does not require any special storage conditions.
Za shranjevanje zdravila Clopidogrel BMS, ki je na voljo v aluminijastih pretisnih omotih, niso potrebna posebna navodila.
• Patients suffering from acute coronary syndrome: - Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).
akutni koronarni sindrom brez elevacije ST spojnice (nestabilna angina ali miokardni infarkt brez Q zobca), vključno z bolniki, katerim je bil vstavljen stent po perkutani koronarni intervenciji, v kombinaciji z acetilsalicilno kislino (ASA - acetylsalicylic acid).
Intermediate metabolism: CYP2C19*1/*2 or *1/*3
Srednja presnova: CYP2C19*1/*2 ali *1/*3
However, patients entered into clinical trials with clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers, ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, and GPIIb/IIIa antagonists without evidence of clinically
Vendar pa so bolniki, ki so bili vključeni v klinično preskušanje klopidogrela, prejemali sočasno različna zdravila, vključno z diuretiki, zaviralci adrenergičnih receptorjev beta, zaviralci angiotenzinske konvertaze (ACEI), kalcijevimi antagonisti, učinkovinami za zniževanje holesterola, koronarnimi vazodilatatorji, antidiabetiki (vključno z insulinom), antiepileptičnimi učinkovinami in antagonisti glikoproteina IIb/IIIa, brez dokazov o klinično
Bullous dermatitis (toxic epidermal necrolysis, Stevens Johnson Syndrome, erythema multiforme), angioedema, rash erythematous, urticaria, eczema, lichen planus Musculo-skeletal bleeding (haemarthrosis), arthritis, arthralgia, myalgia
Bulozen dermatitis (toksična epidermalna nekroliza, StevensJohnsonov sindrom, multiformni eritem), angioedem, eritematozen izpuščaj, urtikarija, ekcem, lihen planus
The number of patients experiencing the co-primary endpoint (CV death, MI, stroke or refractory ischaemia) was 1,035 (16.5%) in the clopidogrel-treated group and 1,187 (18.8%) in the placebotreated group, a 14% relative risk reduction (95% CI of 6%-21%, p=0.0005) for the clopidogrel-treated group.
Število bolnikov s primarnim opazovanim dogodkom (srčno-žilna smrt, MI, kap ali neodzivna ishemijo) je bilo 1.035 (16,5 %) v skupini zdravljeni s klopidogrelom in 1.187 (18,8 %) v skupini s placebom, to je 14 % zmanjšanje relativnega tveganja (95 % IZ od 6 % -21 %, p=0,0005) za skupino, zdravljeno s klopidogrelom.
Bruising
Vrtoglavica
After repeated doses of 75 mg clopidogrel per day in subjects with severe renal disease (creatinine clearance from 5 to 15 ml/min), inhibition of ADP-induced platelet aggregation was lower (25%) than that observed in healthy subjects, however, the prolongation of bleeding time was similar to that seen in healthy subjects receiving 75 mg of clopidogrel per day.
Po večkratnih odmerkih 75 mg klopidogrela na dan, je bila pri osebah s hudo ledvično boleznijo (očistek kreatinina 5 do 15 ml/min)inhibicija z ADP sprožene agregacije trombocitov manjša (25 %) od tiste, opažene pri zdravih osebah.
• if you have had a clot in an artery of your brain (ischaemic stroke) which occurred within the
• če ste imeli strdek v možganski arteriji (ishemična kap), ki se je pojavil v zadnjih sedmih dneh
For the maintenance dose, clopidogrel should be given as a single daily dose of 75 mg with or without food.
Za vzdrževalno zdravljenje je treba klopidogrel uporabljati v enkratnem odmerku 75 mg na dan, s hrano ali brez nje.
Fifteen percent (15.0%) of patients in the clopidogrel group and 21.7% in the placebo group reached the primary endpoint, representing an absolute reduction of 6.7% and a 36 % odds reduction in favor of clopidogrel (95% CI: 24, 47%; p < 0.001), mainly related to a reduction in occluded infarct-related arteries.
Primarni opazovani dogodek je bil opažen pri 15,0 % bolnikov v skupini s klopidogrelom in 21¸7 % bolnikov v skupini s placebom, kar predstavlja absolutno zmanjšanje za 6,7 % in 36 % zmanjšanje verjetnosti v prid klopidogrela (95 % IZ od 24 % do 47 %; p < 0,001) v glavnem zaradi zmanjšanja zaradi infarkta zamašenih arterij.
− Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction): clopidogrel treatment should be initiated with a single 300 mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA) 75 mg-325 mg daily).
- Akutni koronarni sindrom brez elevacije ST spojnice (nestabilna angina ali miokardni infarkt brez Q zobca): zdravljenje moramo začeti z enkratnim udarnim odmerkom 300 mg klopidogrela in nadaljevati s 75 mg enkrat na dan (s 75 mg do 325 mg acetilsalicilne kisline (ASA) dnevno).
In PVC/PVDC/aluminium blisters, store below 30°C.
V PVC/PVDC/alu pretisnih omotih shranjujte pri temperaturi do 30°C.